In late August 2023, the U.S. Department of Health and Human Services (HHS) suggested a notable change in marijuana classification that might significantly shift the landscape of the industry. The HHS recommended rescheduling marijuana from a Schedule I substance, currently classified as having no medical use and a high potential for abuse, to a Schedule III substance under the Controlled Substances Act (CSA). Schedule III substances are acknowledged to have potential medicinal value and a lower risk of misuse, indicating a drastic potential shift in the U.S. marijuana market. Here is more on the subject.
This proposed change comes seven years after the Drug Enforcement Administration (DEA) declined to initiate rulemaking to reschedule marijuana, revealing what appears to be a changing tide in government perception of marijuana. Accordingly, this recommendation by the HHS could potentially initiate a watershed moment in marijuana legislation, possibly leading to the liberalisation of laws around marijuana for medicinal and possibly even recreational use in the U.S.
Further changes on the horizon include the Secure and Fair Enforcement (SAFER) Banking Act, which aims to remove limitations on banks and allow them to freely do business with marijuana-related enterprises without the risk of federal reprisal. This legislative change, if passed, would have profound implications for the marijuana market, making it easier for marijuana-related businesses to secure funding and operate like other legal entities. This would undoubtedly generate a more favourable environment for those enterprises seeking to compete in the marijuana market.
The timeline for the implementation of these changes, however, remains uncertain. As legal professionals working with global corporations and law firms move forward, it is certainly a development to keep under close observation.